ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PBX Probiotix Health Plc

3.25
0.00 (0.00%)
26 Jul 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Probiotix Health Plc AQSE:PBX Aquis Stock Exchange Ordinary Share GB00BLNBFR86
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.25 2.00 7.00 4.50 2.60 3.25 11,015 14:29:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Probiotix Health Share Discussion Threads

Showing 51 to 73 of 250 messages
Chat Pages: 10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
12/12/2023
10:04
I think that LPldl products have more potential than SlimBiome products. Steen A seems to have a bit of experience in growing companies and then selling. But I do get the impression PBX is taking a step backwards to hopefully make bigger steps forward in the future. IE putting a strategy in place in the 1st year of Steen's tenure. Up to him to prove it works.

Like many/most/all AIM companies, you have to wait and see hard evidence before you can believe anything.

m4rtinu
12/12/2023
08:27
I always believed pbx had more potential than slimbiome when it was under the OptiBiotix umbrella. Whether Steen can realise that potential is the question now?
jmf69
11/12/2023
18:06
So would I :)
m4rtinu
11/12/2023
15:23
Thanks Martin.Last year orders to the end of August were 1.1m and year end sales were 1.3m.On that basis, sales should be approximately 1.8m? I would like more regular updates from Steen and the team.
jmf69
11/12/2023
15:00
Here it is: (I guess you've seen this).

"During the first half of the financial year the Group received confirmed orders totalling £1.5m which is 16% greater than turnover for the period to 31 December 2022 of £1.31m. Of the orders received, £552k (2021: £302k) had been completed and invoiced as at 30 June 2023. The increase in sales for the first half of the year reflects strong development in new customer acquisition as well as growth from existing customers. Gross profit for the period amounted to £264k (2022: £154k)."

Let's see if " completed sales" are anything like as positive as that might be interpreted. But as I say, will be long way from net profit. Cheers. MU.

m4rtinu
11/12/2023
09:28
Not sure whether to take the complete lack of news from pbx as a bad sign?? Usually is bad. 1.3m sales last year and H1 2023 sales I found to be disappointing.
jmf69
07/12/2023
20:09
SEED DS-01Probiotics are by now well-established as a way of positively impacting not just the gut but the rest of the body -  and mood (increasingly the significance of the mind-gut relationship is being proven in studies, with a good, diverse gut bacteria profile being shown to have a positive effect). But not all probiotics make it into the gut itself. Seed DS-01 has been engineered to get there, surviving acid, enzymes, moisture, and heat so it can deliver live prebiotics and 24 strains of probiotics through to the end of the small intestine for delivery into the colon. Unsurprisingly, it's won awards. Surprisingly, it is not yet mainstream. That looks likely to change this year.
jmf69
07/12/2023
20:08
hTtps://www.standard.co.uk/lifestyle/wellness/new-supplements-vitamins-for-health-b1124666.html
jmf69
07/12/2023
07:30
Can see the board on the app now
jmf69
25/7/2023
11:12
:) No bother.
m4rtinu
25/7/2023
10:47
I have no idea myself, thanks for the link.
stirkjames
25/7/2023
10:23
Cos I'm incapable. Not so straightforward with AQSE ticker. But if you look above in my introduction I have just put a link to HL site which shows live price and tab for chart.

If you can tell me how to do the chart I'll try. But I had several goes before and failed. Also, SR trashed one of my other attempts so I left him to talk to himself! Cheers. MU.

m4rtinu
25/7/2023
10:18
Why don't you put a chart on your header so we can see the share movement?
stirkjames
25/7/2023
10:15
This is on the move.
m4rtinu
29/6/2023
23:04
Just read the full report. 😂

Another POS spin out

only 1 pinnochio
29/6/2023
22:57
Hello

A loss and an outlook with no figures? .

Sounds familiar

only 1 pinnochio
29/6/2023
22:33
pj = FAILURE
kumbuka
29/6/2023
22:33
WARNING is pj is involved the company is certain to be an investment to stay away from and it might also be SCAM
kumbuka
29/6/2023
22:32
Pretty good line up of losers bully boy pj

PEL, SBTX, OPTI, MIN, INSG, INL and FLX

kumbuka
29/6/2023
22:30
Anything that bully boy pj is involved in is laughable LOL
kumbuka
29/6/2023
22:06
Have I got this right?

X3 Board of Directors to generate £1.75m Revenue in a growth sector??

It's nothing short of laughable if my figures are correct.

pj 1
28/6/2023
10:19
Some extracts from the "Outlook"

ProBiotix has traded strongly since the beginning of the new financial year and has a strong order book from existing and new customers. Our CEO Steen Dannemann Andersen is already leveraging his industry-leading contacts to introduce
ProBiotix to new customers, some of which – including SymbioPharm one of the top three probiotic brands in Germany – have already placed a significant order.

We are also enjoying continued strong growth in e-commerce sales direct to consumers albeit ongoing issues with our supply chain has impacted on the availability of our best-selling product CholBiomeX3. The Company identified a new
manufacturer in 2022 and first orders were supplied in H1 2023.

CEOs strategy

...

In the first phase of implementation of this strategy, we will concentrate on expanding our sales structure in Europe and the Middle East, and building a platform for growth in North America, before moving in the medium term to explore the potential of additional markets in the Asia Pacific region, South America and South Africa. We will also seek to prove the potential for direct-to-consumer sales, focusing initially on the UK.

This strategy presents a clear five-year pathway for ProBiotix Health to build annual sales of £10 million while shifting the balance of the business from deriving 85% of turnover from bulk sales of LPLDL® in 2022 to making 85% of sales from finished products. To support this new strategic focus and ensure the delivery of the expected results we will need to make changes to the internal structure of the business and recruit additional personnel, including a
sales director for Europe and the Middle East and new sales manager for North America, together with an operations manager and a development scientist to add impetus to our product development.

Recruitment and additional staffing costs mean that whilst we expect sales to grow in 2023 the additional investment will impact on profitability in 2023, but will form a much stronger platform to deliver growth and shareholder value in the medium and longer term.

m4rtinu
28/6/2023
09:32
Results. Odd reporting period of c. 13 months. Why not 9? Loss £200k+.
m4rtinu
Chat Pages: 10  9  8  7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock